iCAD, Inc.
- Jurisdiction
United States - ISIN
US44934S2068 (ICAD )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
7
/ 7
Profile
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. Read full profile
Stock price
Fundamentals
- Net revenue
€16.72M - Gross margin
85.6% - EBIT
-€5.10M - EBIT margin
-30.5% - Net income
-€4.47M - Net margin
-26.8%
Statement period: - (published )
Dividends
No dividend payouts
Earnings Calls
Latest earnings call: May 15, 2024
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Buy |